Operator of a cancer research company intended to develop a method of coating active substances with nano-particles of polysaccharides. The company's novel technology transforms generics to super-generics via a dextran-based nano-particle delivery system and exhibits dramatically improved tumor targeting, thereby enabling medical professionals in enhancing therapy efficacy while minimizing adverse effects on healthy tissues.